Cardio Diagnostics Holdings, Inc. specializes in creating and bringing to market advanced clinical diagnostic tools that leverage epigenetic insights to address cardiovascular disease. Among their key offerings is Epi+Gen CHD, a test designed to assess an individual's three-year risk for developing symptomatic coronary heart disease. This company, headquartered in Chicago, Illinois, was established in 2017.
Sector: In Vitro & In Vivo Diagnostic Substances
Industry: Biotechnology
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 2.96M shares outstanding
USCardio Diagnostics Holdings, Inc. specializes in creating and bringing to market advanced clinical diagnostic tools that leverage epigenetic insights to address cardiovascular disease. Among their key offerings is Epi+Gen CHD, a test designed to assess an individual's three-year risk for developing symptomatic coronary heart disease. This company, headquartered in Chicago, Illinois, was established in 2017.
James Intrater
Director
Meeshanthini V. Dogan, PhD
Chief Executive Officer and Director
Paul F. Buton
Director
Peter K. Fung, MD
Director
Employees
13
Country
US
Sector
Healthcare
Website
cardiodiagnosticsinc.com
Loading congressional disclosures…
based on 2.96M shares outstanding
US30d Avg
31.97K
60d Avg
37.94K
90d Avg
56.66K
